Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Nck SH3 domain 1** (Nck SH3.1) is the first Src homology 3 domain in the Nck adapter proteins (Nck1 and Nck2), which are composed of one SH2 and three SH3 domains[1][3][6]. The SH3.1 domain specifically binds to proline-rich motifs, notably the PxxDY sequence present in signaling proteins such as the CD3ε chain of the T cell receptor (TCR), and mediates the assembly of signaling complexes crucial for cytoskeletal remodeling and receptor-initiated signaling cascades[1][6]. This binding regulates downstream signaling pathways involved in cell migration, immune synapse formation, and cytoskeletal reorganization[1][3][4][6]. In cancer and immune-related diseases, dysregulation of Nck SH3.1 interactions can lead to altered cell movement and proliferation. While not currently a direct therapeutic drug target, Nck SH3.1 is a validated node for small-molecule or peptide inhibitors aiming to disrupt pathological protein–protein interactions[2].
Inhibition or modulation of protein–protein interaction between Nck SH3.1 and its proline-rich ligands
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nck SH3 domain 1 (Nck SH3.1).